Pseudoprogression and Measurement Variability

Affiliations

Comment

Mizuki Nishino. J Clin Oncol. 2016.

. 2016 Oct 1;34(28):3480-1.

doi: 10.1200/JCO.2016.67.6759. Epub 2016 Jul 25.

¹ Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA mizuki_nishino@dfci.harvard.edu.

No abstract available

Comment in

Reply to M. Nishino.
Hodi FS, Wolchok JD. Hodi FS, et al. J Clin Oncol. 2016 Oct 1;34(28):3481. doi: 10.1200/JCO.2016.69.1097. Epub 2016 Jul 25. J Clin Oncol. 2016. PMID: 27458281 No abstract available.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD. Hodi FS, et al. J Clin Oncol. 2016 May 1;34(13):1510-7. doi: 10.1200/JCO.2015.64.0391. Epub 2016 Mar 7. J Clin Oncol. 2016. PMID: 26951310 Free PMC article. Clinical Trial.